You are here

Pfizer Breaks Ground On New Biologics Clinical Manufacturing Facility In Andover, Massachusetts

Thursday, June 16, 2016 - 8:30am
EDT

Pfizer Inc. today broke ground for its new biologics clinical manufacturing facility in Andover, Massachusetts. Expanding the company’s presence in the state, Pfizer will invest more than $200 million in development of the 175,000 sq. ft. state-of-the-art facility that will enable the production of high-quality, complex biologics and vaccines. The new 5-story building is expected to be operational by January 2019. Approximately 75 new employees will be hired to support clinical manufacturing. In addition to the Andover campus, Massachusetts is home to Pfizer’s Research and Development hub in Cambridge. Pfizer has approximately 2,000 employees based in Massachusetts.

Pfizer’s Andover campus currently includes 7 buildings which house laboratories, clinical and commercial manufacturing suites, and support areas. It also includes a multiproduct manufacturing facility, which allows clinical and commercial products to be manufactured simultaneously, supporting a range of Pfizer product supply.

The new clinical manufacturing facility is designed with 5 independent manufacturing suites to support Pfizer’s highly complex and diverse biologics research effort. The facility will:

  • Employ flexible design to fully enable Next Generation Manufacturing strategies
  • Leverage state-of-the-art single-use bioreactors and disposable process technologies
  • Provide clinical manufacturing options with the lowest cost and greatest flexibility for efficiently driving important clinical drugs to patients

“The expansion of Pfizer’s presence in Andover will provide state-of-the-art manufacturing to help bring new medicines and vaccines to the patients we serve,” said John Ludwig, senior vice president, BioTherapeutics Pharmaceutical Sciences in Pfizer R&D. “Andover is a crucial part of our global footprint for both clinical and commercial manufacturing, and we believe it provides an attractive location for growth in the coming years.”

"Pfizer's decision to expand their campus in Andover speaks to the Commonwealth's continued global leadership in biopharma and our administration's support of the growing advanced manufacturing sector," said Lieutenant Governor Karyn Polito. "We are pleased to have Pfizer operating in Andover, Boston and Cambridge and look forward to their ongoing contributions to the Massachusetts's economy and wellbeing of our citizens.”

“This five-story building will add 75 new permanent manufacturing jobs and 200 temporary construction jobs to Pfizer’s Andover campus, already home to 1,200 employees,” Senator Barbara L’Italien said. “This project is a testament to Pfizer’s commitment to Andover and I look forward to the facility opening in early 2019.”

Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer healthcare products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. For more information, please visit us at www.pfizer.com. In addition, to learn more, follow us on Twitter at @Pfizer and @Pfizer_newsLinkedIn,YouTube, and like us on Facebook atFacebook.com/Pfizer.

Disclosure Notice: The information contained in this release is as of June 16, 2016. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about Pfizer’s new biologics clinical manufacturing facility in Andover, Massachusetts, including its potential benefits and the anticipated timing of completion, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the ability to realize the anticipated benefits of the new facility and the ability to complete construction in the anticipated timeframe or at all; other business effects, including the effects of industry, market, economic, political or regulatory conditions; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

Contact: 

Dean Mastrojohn, 917-580-2423

Dean.Mastrojohn@Pfizer.com